NCT01902758

Drug Combination on Exercise Performance at High Altitude

Enhancing Physical Performance and Mitigating Acute Mountain Sickness Via Pharmaceutical Intervention While at Altitude

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: University of Montana · Academic / Other
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This study is being conducted to determine the effectiveness of using two FDA approved medications in concert to reduce the likelihood of sickness due to low oxygen levels and to reduce the decrement in physical performance at higher elevations. The investigators hypothesize that this drug combination will reduce the symptoms of acute mountain sickness and improve exercise performance at high altitude compared to placebo.

Conditions

• Acute Mountain Sickness

Interventions

Type	Name	Description
DRUG	ambrisentan and theophylline
DRUG	placebo	placebo for comparison group

Timeline

• Start date: 2013-08-01
• Primary completion: 2013-08-01
• Completion: 2013-08-01
• First posted: 2013-07-18
• Last updated: 2016-02-26
• Results posted: 2016-01-25

Locations

1 site across 1 country: United States